Story
Tesla's Optimus Robot Production Hindered by Complex Hand Assembly: Report

Summary
Tesla is reportedly facing significant manufacturing bottlenecks with its Optimus humanoid robot, specifically with the complex assembly of its hands, threatening near-term production goals.
Tesla Inc. is encountering significant challenges in scaling the production of its Optimus humanoid robot, with the intricate assembly of the robot's hands emerging as a primary manufacturing bottleneck, according to a report from The Information.
Production Targets Under Pressure
While Tesla has reportedly increased Optimus output tenfold in recent months, from several dozen units per week in the second quarter to several hundred currently, the company is struggling to reliably scale further. The report attributes the slowdown to a combination of factors:
- Complex Hand Assembly: The detailed mechanical requirements for the robot's hands are proving difficult to manufacture at scale.
- Supplier Constraints: Issues with parts suppliers are contributing to the delays.
- Equipment Failures: Automated manufacturing equipment has reportedly experienced failures.
These hurdles challenge Tesla's aggressive production targets, which aim for 1,000 robots per week by the end of the year and an eventual goal of 20,000 units weekly.
A Controlled Commercial Rollout
AdThe current model, the Fremont-built Optimus V3, is not yet a general-purpose machine. It operates in supervised testing areas and factory floors performing specific, pre-programmed tasks. The AI driving the robot has been trained on over 500,000 hours of real-world data, according to the report.
Given that the V3 is not the final consumer version, Tesla is planning a tightly controlled initial commercial launch. The Information notes that early units will be leased, not sold, to customers with warehouse environments similar to Tesla's own. This lease-only strategy allows Tesla to retrieve the hardware for mechanical upgrades while continuously collecting factory data to refine its AI.
Long-Term Vision vs. Near-Term Reality
CEO Elon Musk has repeatedly positioned Optimus as Tesla's most important future product, with the potential to transform the company's valuation. However, the current manufacturing difficulties highlight the significant engineering and logistical challenges that must be overcome.
The company reportedly hopes to begin full commercial sales by late 2027. Achieving this timeline will depend on resolving the complex production issues, particularly the manufacturing of one of the robot's most critical and human-like components: its hands.
Read next
More on Stocks
Nanexa Shares Soar Over 100% After Securing Licensing Pact with Novo Nordisk
Shares of Swedish biotech firm Nanexa AB surged after it announced a global licensing agreement with Novo Nordisk potentially worth up to €1.165 billion for its PharmaShell drug-delivery platform.

IREN Stock Slides as Competitor's IPO Filing Pressures AI Infrastructure Sector
Shares of IREN slid more than 5% amid a sector-wide selloff in AI cloud providers, sparked by a competitor's IPO filing that has raised investor concerns over valuations and pricing power.

Super Micro Computer Stock Climbs on NVIDIA Vera Rubin System Shipments
Shares of Super Micro Computer advanced after the company announced it began shipping its new liquid-cooled rack systems featuring NVIDIA's latest Vera Rubin architecture, a key milestone for its AI infrastructure business.

Celestica Stock Climbs on Pre-Earnings Optimism and Positive Analyst Sentiment
Celestica shares gained nearly 1% as investors positioned ahead of late October's Q3 earnings report and Investor Day. The advance is supported by positive analyst ratings and a strong market narrative around the company's role in AI infrastructure.